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Abstract
During the last decade, there has been a remarkable and unexplained increase in the prevalence of 
asthma. These studies were conducted to investigate the role of dermal exposure to triclosan, an 
endocrine-disrupting compound, on the hypersensitivity response to ovalbumin (OVA) in a 
murine model of asthma. Triclosan has had widespread use in the general population as an 
antibacterial and antifungal agent and is commonly found in consumer products such as soaps, 
deodorants, toothpastes, shaving creams, mouthwashes, and cleaning supplies. For these studies, 
BALB/c mice were exposed dermally to concentrations of triclosan ranging from 0.75 to 3% 
(0.375–1.5 mg/mouse/day) for 28 consecutive days. Concordantly, mice were ip injected with 
OVA (0.9 μg) and aluminum hydroxide (0.5 mg) on days 1 and 10 and challenged with OVA (125 
μg) by pharyngeal aspiration on days 19 and 27. Compared with the animals exposed to OVA 
alone, increased spleen weights, OVA-specific IgE, interleukin-13 cytokine levels, and numbers of 
lung eosinophils were demonstrated when mice were coexposed to OVA and triclosan. 
Statistically significant increases in OVA-specific and nonspecific airway hyperreactivity were 
observed for all triclosan coexposed groups compared with the vehicle and OVA controls. In these 
studies, exposure to triclosan alone was not demonstrated to be allergenic; however, coexposure 
with a known allergen resulted in enhancement of the hypersensitivity response to that allergen, 
suggesting that triclosan exposure may augment the allergic responses to other environmental 
allergens.
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Triclosan (2,4,4′-trichloro-2′-hydroxydiphenyl ether) is a high volume production chemical 
that is widely used occupationally with up to 10 million pounds produced annually in the 
United States alone (FDA, 2008). Triclosan has antimicrobial and antifungal properties and 
has been used in the United States for more than 40 years. It was originally introduced as an 
additive to medical devices such as sutures to inhibit bacterial growth in wounds (Ming et 
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al., 2007). Although there is evidence for the efficacy of triclosan in clinical applications, its 
current major use is in consumer products including antibacterial soaps (0.10–1.00%), 
deodorants (0.0375%), toothpastes (0.3%), shaving creams, skin creams (0.1%), 
mouthwashes, feminine hygiene products, and cosmetics (Fang et al., 2010). Triclosan is 
also used as a preservative, fungicide, and biocide in household cleaning products and is 
infused into other household items such as kitchen utensils, cutting boards, kitchen wipes, 
mop heads, computer equipment, clothing, air filters, flooring, toys, bedding, and trash bags 
(Fang et al., 2010; Glaser, 2004). It was demonstrated that showering or bathing with 2% 
triclosan is an effective regimen for the decolonization of patients' skin carrying methicillin-
resistant Staphylococcus aureus (Jones et al., 2000). Research suggests that beyond its use 
in clinical applications and toothpaste to prevent gingivitis (Gunsolley, 2006), there is 
questionable evidence that triclosan provides any extra benefit in other consumer products 
(Tan et al., 2002).
There are limited studies evaluating the toxicity of triclosan; however, in general, it has been 
shown to exhibit low oral and dermal toxicity, with some evidence of higher toxicity via 
inhalation (DeSalva et al., 1989; Fang et al., 2010). Triclosan is not considered to produce 
significant mutagenic effects or genotoxicity (DeSalva et al., 1989); however, the 
carcinogenicity studies that have been conducted have been described as contradictory 
and/or inadequate (DeSalva et al., 1989; FDA, 2008; Lyman and Furia, 1969). 
Developmental and reproductive effects have recently been suggested (Paul et al., 2012; 
Stoker et al., 2010). In general, triclosan has not been reported as a skin sensitizer when 
tested in animal models (DeSalva et al., 1989; Lyman and Furia, 1969) or in humans 
(DeSalva et al., 1989; Kligman and Epstein, 1975; Marzulli and Maiback, 1973) although 
rare case reports have been described (Savage et al., 2011; Steinkjer and Braathen, 1988).
Numerous reports suggest that triclosan is an endocrine-disrupting compound (EDC). EDCs 
have deleterious effects on human health, homeostasis, metabolism, and reproduction by 
mimicking or affecting hormones (Diamanti-Kandarakis et al., 2009). Studies have shown 
that triclosan is weakly androgenic (Foran et al., 2000) and estrogenic (Gee et al., 2008). 
Additionally, triclosan has been shown to disrupt thyroid homeostasis in mammalian 
models. It has been suggested that exposure to EDCs, including triclosan, is at least in part 
responsible for recent changes in the frequency of asthma and allergic responses (Clayton et 
al., 2011, Savage et al., 2012). A study conducted between 2003 and 2006 found a positive 
association between elevated urinary triclosan levels and allergy or hay fever diagnosis, but 
not cytomegalovirus antibody titers, and concluded that triclosan may negatively affect the 
immune system (Clayton et al., 2011). A more recent study using data from 860 children 
obtained from the 2005–2006 National Health and Nutrition Examination Survey found 
levels of urinary triclosan to be positively associated with aeroallergen and food 
sensitization (Savage et al., 2012).
Triclosan has recently attracted the attention of the scientific community, regulatory 
agencies, and the general public because of its high production volume, widespread 
applications, and endocrine-disruption effects. In spite of the epidemiologic evidence of a 
potential role for triclosan in allergic disease, there are no animal studies in the current 
literature that have examined the contribution of triclosan to asthma pathogenesis. These 
Anderson et al. Page 2













studies characterize the immunomodulatory effects of triclosan following dermal exposure 
in a murine model of asthma.
Materials and Methods
Animals
Female BALB/c mice were used for the murine model. This mouse strain has a Th2 bias and 
is commonly used to evaluate IgE-mediated sensitization (Fairley et al., 2007). The mice 
were purchased from Taconic (Germantown, NY) at 6–8 weeks of age. Upon arrival, the 
animals were allowed to acclimate for a minimum of 5 days. Each shipment of animals was 
randomly assigned to treatment group, weighed, and individually identified via tail tattoo. A 
preliminary ANOVA on body weights was performed to ensure a homogeneous distribution 
of animals across treatment groups. Animals were housed at a maximum of five per cage in 
ventilated plastic shoebox cages with hardwood chip bedding. NIH-31 modified 6% 
irradiated rodent diet (Harlan Teklad) and tap water from water bottles were provided. The 
temperature in the animal facility was maintained between 68°F and 72°F and the relative 
humidity between 36 and 57%. The light/dark cycle was maintained on 12-h intervals. All 
animal experiments were performed in the Association for Assessment and Accreditation of 
Laboratory Animal Care accredited National Institute for Occupational Safety and Health 
animal facility in accordance with an animal protocol approved by the Institutional Animal 
Care and Use Committee.
Chemicals
All chemicals, triclosan (CAS no. 3380-34-5), chicken egg ovalbumin (OVA; CAS no. 
9006-59-1), methacholine chloride (Mch; CAS no. 101-86-0), and aluminum hydroxide 
(Alum; CAS no. 1330-44-5), were purchased from Aldrich Chemical Company, Inc. 
(Milwaukee, WI).
Triclosan Exposure
Mice (eight per group) were exposed topically to acetone or increasing concentrations of 
triclosan (up to 1.5 mg/per mouse) dissolved in acetone (99.5%) on the dorsal surface of 
each ear (25 μl per ear) for 28 consecutive days. The highest concentration of triclosan (1.5 
mg/3%) for these studies was selected based on the results from a dermal toxicity study 
(Fang et al., 2010) conducted in male mice where the lowest observable effect limit (LOEL) 
for dermal exposure was found to be 1.5 mg/animal/day. The LOEL was based on 
treatment-related dermal irritation at the treatment site and on increased liver weights in this 
treatment group. Acetone is an accepted vehicle for the murine local lymph node assay, 
which is used to evaluate skin sensitizers. Therefore, based on this and solubility, it was 
selected as the vehicle for the dermal triclosan exposures. In studies presented here, mice 
were simultaneously sensitized to OVA (dissolved in sterile PBS) as previously described 
by ip injection and pulmonary aspiration (Fairley et al., 2007). In brief, animals were 
exposed to OVA (0.9 μg OVA + 0.5 mg Alum/200 μl PBS) or 0.5 mg Alum/200 μl sterile 
PBS by ip injection on days 1 and 7. Mice were then challenged with OVA (125 μg/50 μl 
sterile PBS) or 50 μl sterile PBS via pharyngeal aspiration under light anesthesia (isofurane) 
on days 19 and 27 using oropharyngeal aspiration as previously described (Rao et al., 2003). 
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The study consisted of five groups that are represented by their specific exposure scenario: a 
vehicle control (VC: acetone[dermal]/PBS[pulmonary]), OVA control (OVA: 
acetone[dermal]/OVA[pulmonary]), and three coexposure groups (0.75, 1.5, or 3% 
triclosan[dermal]/OVA[pulmonary]). Although the animals were simultaneously exposed to 
OVA and triclosan, it was through different exposure routes, and therefore, there was never 
a mixture of triclosan and OVA being administered to the animals.
Hematology
Selected hematological parameters were evaluated using an automatic hematology analyzer 
(Hemavet 950; Drew Scientific, Waterbury, CT): erythrocyte and leukocyte counts, 
leukocyte differential (lymphocytes, neutrophils, monocytes, basophils, and eosinophils), 
platelet count, hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration, mean platelet volume, and platelet distribution width.
Airway Hyperreactivity
Nonspecific airway hyperreactivity (AHR) and specific AHR were evaluated and expressed 
as enhanced pause (Penh), a dimensionless parameter used to measure pulmonary resistance, 
calculated from changes in the pattern of chamber pressure induced by airway challenge.
Nonspecific challenge—Forty-eight hours after the first OVA challenge on day 21, 
AHR was assessed. An initial 5-min baseline reading was obtained prior to challenge with 
increasing concentrations of aerosolized Mch (10, 25, and 50 mg/ml in PBS). For each 
concentration of Mch, average Penh values were collected every 30 s for 5 min. Mch 
exposure occurred only for the first 3 min of this 5-min period. During the final 2 min, mice 
were exposed to fresh air alone. Average Penh values for each 5-min period were used as the 
measure of AHR.
Specific challenge—On day 27, immediately following the final pulmonary OVA 
challenge, AHR was assessed as changes in airway function following specific allergen 
challenge (OVA) using the Buxco unrestrained whole body plethysmography system 
(Buxco Research Systems, Wilmington, NC). Airway measurements (Penh) were collected 
over a 6-h period. Data were presented as area under the curve (AUC). On day 28, 24 h after 
the final OVA challenge, mice were euthanized by an overdose of pentobarbital (injected 
ip). Body and organ weights were measured, the tracheobronchial lymph nodes (TBLN) and 
whole lungs were collected for cytokine analysis, blood was collected by transection of the 
abdominal aorta for antibody (IgE and IgG1) analysis and hematological analyses, 
bronchoalveolar lavage (BAL) fluid was collected for analysis of cellular infiltrates, and 
histopathologic analysis was performed on lung tissue from a representative animal from 
each exposure group.
OVA-Specific ELISA
Standard colorimetric sandwich ELISAs were performed on serum collected from 
experimental animals. For the OVA-specific IgE ELISA, the antibodies and standard 
controls were purchased from BD Pharmingen (San Jose, CA) and Genway (San Diego, 
CA). In brief, 96-well fat bottom plates (Immunlon-4HBX) were coated with (2 μg/ml in 
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PBS) purified monoclonal rat anti-mouse IgE antibody (clone R35-72) and incubated 
overnight at 4°C. The plates were washed thrice with PBS/Tween and then blocked for 1 h 
with diluent (PBS/1% nonfat milk) at room temperature. Serum samples were diluted 1:10, 
and the IgE control standard (anti-OVA IgE; Genway Cat no. 20-783-71815) was prepared, 
added to the coated plates, and incubated at room temperature for 1 h. The plates were then 
washed, OVA (25 μg/ml; Sigma Cat no. A-5503) was added, and plates were incubated at 
room temperature for 1 h. The plates were washed, rabbit anti-OVA horseradish peroxidase 
(Genway Cat no. 18-272-197841; 1:8000 dilution) was added, and plates were incubated for 
1 h at room temperature. The anti-Ovalbumin IgG1 (mouse) EIA Kit (Item No. 500830) 
purchased from Cayman Chemical Company (Ann Arbor, MI) was used according to 
manufacturer's directions. In brief, serum samples were diluted 1:30,000, added to the 96-
well precoated plate provided in the kit, and incubated at room temperature for 2 h on an 
orbital microplate shaker at 100–250 rpm. The plate was washed four times, and detection 
antibody working solution was added to the plate. The plate was then incubated for 1 h at 
room temperature with shaking. To stop the final enzymatic reaction for both the IgE and 
IgG1 assay, 3,3′,5,5′-tetramethylbenzidine (Sigma Cat no. T4444) was added to the plates, 
which were then incubated at room temperature until color change. The reactions were 
stopped with 2N sulfuric acid. Absorbance was determined using a Spectramax Vmax plate 
reader (Molecular Devices, Sunnyvale, CA) at 405 nm. OVA-specific antibody 
concentrations (IgE and IgG1) for each sample were interpolated from a standard curve 
using multipoint analysis.
Bronchial Alveolar Lavage—Cellular Infiltrate Phenotyping
Following euthanasia, lungs were perfused, via the right ventricle of the heart, with 10 ml of 
PBS to remove blood cells present within the lung vasculature. BAL samples were then 
collected by cannulating the trachea of each mouse and lavaging thrice, each time with 1 ml 
of sterile PBS. Approximately 2.5 ml of bronchial lavage fluid was recovered from each 
mouse. Suspended cells were pelleted by centrifugation (5 min at 486 × g) and resuspended 
in 200 μl of flow staining buffer containing the following combinations of fluorochrome-
conjugated antibodies to identify infiltrating eosinophil, neutrophil, and alveolar 
macrophage (CD45-APC, Siglec-F-PE, CD11c-biotin, Ly6G-FITC) populations. Cell 
suspensions were incubated with labeled antibodies on ice in the dark for 30 min and 
washed. Samples stained with biotin labeled anti-CD11c (1:100 dilutions in flow staining 
buffer) were resuspended in flow staining buffer containing streptavidin PerCP, incubated 
for an additional 30 min on ice in the dark, and washed. All samples were then fixed by 
resuspending in 100 μl BD cytofixation buffer (BD Bioscience, San Diego, CA) and 
incubating for 15 min. Cells were then washed, resuspended in flow staining buffer, and 
enumerated using a LSRII Flow Cytometer (Becton Dickinson, San Jose, CA) within 48 h. 
Lung cellular infiltrates were identified phenotypically based upon the distinct expression of 
the following cell surface markers: eosinophils (CD45hi, LY6Glow, Siglec Fhi, CD11clow), 
neutrophils (CD45hi, LY6Ghi, CD11clow), and alveolar macrophages (CD45hi, LY6Glow, 
Siglec Fhi, CD11chi). An aliquot of BAL fluid (10 μl) was counted on a Cellometer Auto A4 
(Nexcelom Bioscience, Lawrence, MA) to determine the total number of cells present.
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Lungs were insufflated with 10% formalin and collected for histopathology. Lung tissues 
were embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin, 
alcian blue/PAS, Geimsa, and toluidine blue, and a representative lung from each group was 
evaluated by a veterinary pathologist. Semiquantitative pathology scores were described as 
the sum of the severity and distribution of the histopathologic changes as previously 
described (Hubbs et al., 2008).
Cytokine mRNA Analysis
Lungs from exposed mice were analyzed for mRNA expression. Lungs were collected in 0.8 
ml of RNAlater (Ambion, Grand Island, NY) and stored at −80°C for subsequent 
processing. RNA was isolated using the miRCURY RNA Isolation Kit (Exiqon, Woburn, 
MA) as specified by the manufacturer. The concentration and purity (260/280) of RNA were 
determined using an ND-1000 spectrophotometer (Thermo Scientific NanoDrop, 
Wilmington, DE). One microgram of RNA was reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) as directed by the 
manufacturer. Relative fold changes in gene expression were assessed using RT-PCR on a 
7500 Fast Real-Time PCR System (Applied Biosystems) using TaqMan PCR Master Mix 
(Applied Biosystems) as specified in the manufacturer's protocol. RT-PCR data were 
collected and expressed as relative fold increase over control, calculated by the following 
formula: 2−ΔΔCt = ΔCtSample − ΔCtControl⋅ ΔCt = CtTarget − CtGAPHD, where Ct is the cycle 
threshold as defined by Control Target GAPDH manufacturer's instructions. Cytokines 
assessed were interferon gamma (IFN-γ) and interleukin (IL)-4, -5, -13, -17, -21, and -22. 
Glyceraldehyde 3-phosphate dehydrogenase was used as the endogenous control.
Ex Vivo Analysis of Cytokine Production From Tracheobronchial Lymph Node Cells
TBLN were collected in 3 ml of sterile PBS. Single cell suspensions of lymph node cells 
were made by grinding the tissue between the frosted ends of two microscope slides. Cells 
were counted using a Coulter Counter (Z1 model; Beckman Coulter, San Jose, CA), 
adjusted to 1 × 106 cells/ml in sterile RPMI media containing 10% fetal calf serum, and 
seeded in 48-well plates (500,000 cells per well). Cells were then stimulated with α-CD3 
and α-CD28 antibodies (2 μg/ml each; BD Pharmingen) for 24 h at 37°C and 5% CO2. 
Supernatants were analyzed for IL-4, IL-5, IL-13, and IFN-γ levels using OptEIA ELISA 
kits purchased from BD Biosciences according to the manufacturer's instructions.
Statistical Analysis
All variables with the exception of Penh were analyzed using GraphPad Prism version 5.0 
(San Diego, CA). Data were first tested for homogeneity using the Bartlett's Chi Square test. 
A one-way ANOVA was conducted. If the ANOVA showed significance at p < 0.05 or less, 
the Dunnett's Multiple Range t -test was used to compare treatment groups with the control 
group. Linear trend analysis was performed to determine whether the test articles had 
exposure concentration–related effects for the specified endpoints. Statistical significance is 
designated by * (p ≤ 0.05) and ** (p ≤ 0.01). SAS/STAT software (Version 9.2 of the SAS 
system for Windows; SAS Institute, Cary, NC) was used to analyze nonspecific AHR using 
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Penh. A two-way factorial ANOVA with concentration of Mch treated as a repeated 
measure to account for multiple measures in individual animals was performed using PROC 
MIXED. Comparisons between treatment groups were then calculated at each level of MCH 
utilizing the “slice” option. Specific AHR was assessed using AUC for the 6-h period 
following the OVA challenge. AUC values across treatment groups were analyzed utilizing 
Proc GLM. Subsequent pairwise comparisons between triclosan exposed animals with either 
vehicle or OVA controls were performed with Fishers' least significant difference test. All 
differences were considered significant at p < 0.05.
Results
Toxicity
There were no deaths in triclosan-exposed animals. During the first 2 weeks of exposure, 
mice dosed with triclosan had a mild degree of irritation (redness, scabbing, etc.) that 
resolved after the 3rd week. There were no significant changes in body weights throughout 
the course of the study (Table 1). All exposure groups had statistically significant increases 
in spleen weights (mg, % bw) compared with the VC (Table 1). Exposure to the highest 
concentration of triclosan (3%) resulted in a statistically significant increase in spleen 
weights (mg) compared with the OVA control. Although this result was not statistically 
significant when evaluated as a percent body weight, there was a dose-responsive trend 
(linear trend test p < 0.05). Hematological analysis demonstrated a statistically significant 
decrease in % lymphocytes (OVA, 0.75% triclosan + OVA, 1.5% triclosan + OVA) along 
with an increase in % neutrophils for the coexposure groups (OVA, 1.5% triclosan + OVA) 
compared with the VC (Table 2). Although there was a general increasing trend in 
eosinophils and basophils for the coexposure groups compared with the OVA control, they 
did not reach statistical significance. There were no other statistically significant changes in 
hematological parameters following exposure (Table 2).
Coexposure of OVA and Triclosan Enhances Nonspecific and Specific AHR
Penh values for the OVA control group were elevated compared with the VC following Mch 
challenge reaching statistical significance after challenge with the 10 mg/ml dose (Table 3). 
Coexposure of triclosan and OVA and challenge with 25 and 50 mg/ml Mch resulted in 
statistically significant enhancements in AHR for all coexposure groups compared with the 
OVA control (Fig. 1A and Table 3). A concentration dose response to triclosan was not 
observed. Specific challenge with OVA resulted in a statistically significant increased AUC 
for all animals coexposed to triclosan and OVA (Table 3, Fig. 1B) compared with the OVA 
alone groups. This response was not dose responsive. Although not statistically significant, 
the AUC for the OVA control group was elevated compared with the VC (Table 3). Results 
from a preliminary study evaluating repeated dermal exposure to triclosan (3%) in the 
absence of OVA did not identify an effect on nonspecific AHR (Supplementary data S1A).
Enhanced Serum Antibody Levels
Serum OVA-specific IgE levels were dose responsively (linear trend test p < 0.05) increased 
from 679 ng/ml ± 136 in the OVA control mice to 1644 ng/ml ± 225 in mice exposed to 3% 
triclosan and OVA (Fig. 2A), where statistical significance was reached. OVA-specific IgG1 
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levels were not significantly elevated for any of the coexposure groups compared with the 
OVA control (Fig. 2B). Antibody levels (OVA-specific IgE and IgG1) were statistically 
increased for all exposure groups compared with the VC (Fig. 2). Results from a preliminary 
study evaluating repeated dermal exposure to triclosan (3%) in the absence of OVA did not 
identify an effect on total serum IgE (Supplementary data S1B).
Increased Lung Eosinophils Following Triclosan and OVA Exposure
A significant increase in the number of BAL cells was observed following OVA treatment 
(18.2 × 105 cells/lung ± 1.5 × 105) compared with the VC (2.1 × 105 cells/lung ± 0.3 × 105) 
(Fig. 3A). The number of total cells was significantly elevated for the 0.75% triclosan + 
OVA group (29.6 × 105 cells/lung ± 1.4 × 105) compared with the OVA control (18.2 × 105 
cells/lung ± 1.5 × 105). The number of eosinophils was statistically significantly increased in 
the 0.75% triclosan + OVA group (14.2 × 105 cells/lung ± 1.0 × 105) compared with the 
OVA control (5.7 × 105 cells/lung ± 1.7 × 105) (Fig. 3B). A significant increase in the 
absolute number of neutrophils was observed for the OVA treatment groups (4.1 × 105 cells/
lung ± 1.2 × 105) compared with the VC (1483 cells/lung ± 1297), but no difference was 
detected when the coexposure groups were compared with the OVA control (Fig. 3C). No 
significant changes in the absolute number of alveolar macrophages were observed for the 
triclosan + OVA groups compared with the OVA control or VC (Fig. 3D). Results from a 
preliminary study evaluating repeated dermal exposure to triclosan (3%) in the absence of 
OVA did not identify any effect on eosinophil number (Supplementary data S1C).
Histology
No significant lesions were observed in the lungs of the representative control mouse (Fig. 
4A). The histopathologic changes associated with combined OVA and triclosan exposure 
included multifocal and coalescent, eosinophilic and plasmacytic bronchointerestitial 
pneumonia with multifocal and coalescent, pleocellular alveolitis with rare giant cells; 
multifocal, eosinophilic vasculitis with associated reactive endothelium; eosinophilic and 
plasmacytic perivascular cuffing; multifocal and coalescent, lymphohistiocytic and 
eosinophilic, pleuritis; multifocal, alveolar epithelial cell hypertrophy and hyperplasia; and 
mucous metaplasia of airway epithelium (Figs. 4B and C). Similar changes were noted in 
the representative mouse from the other combined exposure groups (OVA + 0.75% or 1.5% 
triclosan) (data not shown). Changes in the representative OVA-exposed mouse were noted 
to be similar but with a less striking eosinophilic response and with smaller inflammatory 
foci (Fig. 4D). Significant mast cell infiltration was not seen in toluidine blue–stained lung 
sections in any mouse. The overall histopathology findings were consistent with the findings 
in the BAL fluid.
Increased IL-13 mRNA Expression in Lung Tissue Following Triclosan and OVA Exposure
Supporting its role in promoting mucus secretion, AHR, and tissue remodeling, expression 
of IL-13 mRNA in lung tissue was found to be dose responsively upregulated in all groups 
of animals exposed to triclosan and/or OVA compared with those exposed to VC alone (Fig. 
5). Fold changes of 3.9 (OVA), 12.2 (OVA + 0.75% triclosan), 51.4 (OVA + 1.5% 
triclosan), and 68.2 (OVA + 3.0% triclosan) were obtained with statistical significance 
demonstrated for all coexposure groups compared with VC. Statistical significance was only 
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obtained for the high concentration group compared with the OVA control. Based on this 
preliminary data, no significant modulation of IL-4, IL-5, IL-17, IL-21, IL-22, IL-9, or IFN-
γ mRNA was observed following treatment with any triclosan concentration tested.
Increasing Trend in IL-13 Cytokine Production by Lymph Nodes
An increase in IL-4, IL-5, IL-13, and IFN-γ cytokine production by TBLN was observed for 
all OVA-treated groups compared with the VC (Fig. 6). A dose-responsive trend in IL-13 
production (linear trend test p < 0.05) was observed for the coexposure groups compared 
with the OVA controls (Fig. 6C), with an almost twofold increase in the 3% triclosan + 
OVA (828 ± 155 pg/ml) exposure group compared with the OVA controls (433 ± 92 pg/ml). 
Although IL-4 and IL-5 are also designated as prototypical allergic cytokines, no statistically 
significant changes were observed when coexposed groups were compared with the OVA 
control (Figs. 6A and B). This finding supports the requirement of earlier roles for IL-4 and 
IL-5 in the allergic response such as those essential for driving IgE production and 
promoting the terminal differentiation and survival of eosinophils compared with the later 
roles of IL-13 involved in AHR. No statistically significant change in IFN-γ cytokine 
production compared with the OVA control was observed (Fig. 6D). Results from a 
preliminary study evaluating repeated dermal exposure to triclosan (3%) in the absence of 
OVA did not identify an elevation in IL-13 cytokine levels (Supplementary data S1D).
Discussion
During the last decade, there has been a remarkable and unexplained increase in the 
prevalence of asthma. Some have hypothesized that widespread use of antimicrobial 
ingredients such as triclosan may be a contributing factor. This concept is based on the 
hygiene hypothesis, which proposes that lack of pathogen exposure during development can 
alter the usual development of the immune system by eliminating or changing the 
commensal microbiota (Okada et al., 2010). Although this provides one potential 
explanation, individuals in industrial societies are also exposed to an increasing number of 
man-made chemicals. During the same time span for the observed increases in allergic 
disease, individuals in industrial societies have been exposed to an increasing number of 
chemicals with 50,000 in industrial use and an additional 500 new chemicals being 
introduced yearly. Although many chemicals are known to directly induce asthma, there is 
also the potential for chemicals to function as adjuvants, augmenting the immune response 
induced by other chemical and/or protein allergens. Studies in our laboratory and others did 
not identify triclosan to be a sensitizing chemical (DeSalva et al., 1989; Fang et al., 2010); 
however, in the present studies, dermal exposure to triclosan in the presence of an allergen 
was found to augment the allergic response to that allergen (OVA) in a mouse model of 
asthma. Although this does not support the classification of triclosan as a skin sensitizer, it 
does suggest the potential for a role in chemical adjuvancy.
The high level of consumer exposure to triclosan is reflected by its detection in 
environmental wastewater and presence in human fluids. Triclosan was among the top seven 
organic wastewater contaminants found in samples from a network of 139 streams across 30 
states by the U.S. Geological Survey (Kolpin et al., 2002). Triclosan has been found in 
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drinking water, surface water, wastewater, and environmental sediment (Lindström et al., 
2002). Given the prevalence of triclosan in the environment, it is not surprising that 
measurable levels have been detected in the majority of individuals examined to date 
(Adolfsson-Erici et al., 2002; Calafat et al., 2008; Sandborgh-Englund et al., 2006) The 
primary routes of occupational exposure are through dermal contact and inhalation, and it 
has been estimated that a total of 188,670 employees in 16 different industries were 
potentially exposed to triclosan (www.cdc.gov/noes). Triclosan has been shown to undergo 
dermal absorption in both rodent and to a lesser degree human skin, affording it the potential 
to interact with immune cells in the dermis (Black et al., 1975; Kanetoshi et al., 1992). A 
study conducted by Kanetoshi et al. (1992), which applied [3H] triclosan to mouse skin, 
detected maximum systemic levels between 12 and 18 h postexposure, with the greatest 
concentration in the gall bladder, liver, body fat, lungs, kidneys, blood, heart, testes, spleen, 
and brain. The concentrations of triclosan in consumer products range from 0.1 to 1%, 
which is similar to concentrations tested in the studies described in this article (Fang et al., 
2010). While concentrations up to 3% were tested in these studies for hazard identification 
purposes, significant effects on eosinophil numbers and pulmonary function occurred even 
at the lowest concentration tested (0.75%), further supporting the potential for adverse 
effects at biologically relevant concentrations.
Other endocrine-disrupting chemicals such as phthalates, pesticides, and perfluorinated 
compounds have been associated with allergic disease (Fairley et al., 2007; Kwak et al., 
2009; White et al., 2011). Using the same OVA model of asthma, our lab previously found 
that dermal application of perfluorooctanonic acid simultaneously with exposure to OVA 
augments the allergic response to that allergen (Fairley et al., 2007). Other groups using 
animal models have reported similar adjuvant-like effects following phthalate exposure 
(Larsen and Nielsen, 2007). As reviewed by Chalubinski and Kowalski (2006), endocrine 
disruptors have been shown to modulate the immune system by impacting the T-helper cell 
Th1/Th2 balance and subsequently augmenting cytokine and antibody levels, which could 
cause alterations in allergic responses. With the interaction of the endocrine, nervous, and 
immune systems, it is likely that EDCs such as triclosan may induce multiple organ affects, 
and recent attention has focused on a role for them in the development of asthma and 
allergies. In the development of asthma, it has been demonstrated that danger signals from 
contaminating molecules or environmental exposures may be required for dendritic cell 
activation. Some allergens have intrinsic activating properties, whereas the experimental 
allergen OVA does not (Willart and Lambrecht, 2009). In these studies, using a well-
established model, OVA was administered with the adjuvant Alum to induce murine asthma. 
Although the effects of triclosan on the allergic response to OVA independent of Alum were 
not explored in these studies, coexposure to triclosan in this model enhanced the allergic 
response over that observed with OVA and Alum alone.
A role for the innate immune system in asthma pathogenesis has been reported (Melvin and 
Ramanathan, 2012). For example, a role for toll-like receptors (TLR) in allergic airway 
inflammation has been described, and it has been shown that the amount of 
lipopolysaccharide (LPS) present during sensitization can determine whether Th1 or Th2 
immunity is observed (Eisenbarth et al., 2002). Numerous studies have described effects of 
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triclosan on the innate immune system. In vitro studies highlighting the potential anti-
inflammatory effect of triclosan have demonstrated the inhibition of LPS-stimulated 
expression of TLR signaling molecules, proinflammatory mediators, and the dampening of 
the Th1 cell immune response activation by CD70 suppression (Barros et al., 2010; Mustafa 
et al., 2000). The inhibition and suppression of Th1 cytokines such as IFN-γ have been 
demonstrated to enhance Th2 immunity (Williams et al., 2012). Although LPS stimulation 
was not used in the present asthma model, the findings mentioned above support the notion 
that triclosan exposure is capable of augmenting immune responses by potentially regulating 
danger signals required for immune activation, which could result in polarization to a Th2 
immune response.
Further support for triclosan acting early in the development of sensitization is suggested by 
experiments conducted by Palmer et al. (2012) who demonstrated reduced degranulation of 
an IgE-sensitized mucosal mast cell line (RBL-2H3) following triclosan exposure. These 
findings support the previous findings that mechanism behind the adjuvant-like effects 
observed for triclosan may occur in the early microenvironment prior to or during the 
sensitization process.
Additional studies focusing on identifying a potential biological target have demonstrated 
that triclosan significantly enhanced the binding of [3H] ryanodine to the ryanodine (RyR1) 
receptor, resulting in an increase in cytosolic calcium levels in a calcium signaling bioassay 
screen (Ahn et al., 2008). The RyR1 receptor is expressed on numerous cell types including 
B lymphocytes and dendritic cells (Bracci et al., 2007; Vukcevic et al., 2008). In addition to 
elevating intracellular calcium stores, studies conducted by Vukcevic et al. (2008) found 
that RyR1 activation also caused a very rapid increase in the expression of major 
histocompatibility complex class II molecules on the surface of dendritic cells, suggesting 
that activation of the RyR1 signaling cascade may be critical in early immunity. 
Concomitant activation of ryanodine receptor–induced calcium release together with the 
activation of TLR provided synergistic signals, resulting in dendritic cell maturation and 
stimulation of T-cell functions (Bracci et al., 2007). These types of early signaling events 
are instrumental in the development of the adaptive immune response, and the presence of 
chemicals such as triclosan may amplify signals in the presence of allergens, thereby 
augmenting allergic responses. Increases in calcium levels have been shown to regulate 
many immune pathways. A related study found that increases in calcium levels via the 1,4,5-
trisphosphate receptor, which is similar to the RyR1 receptor, were found to augment the 
asthma hallmark of airway hyperresponsiveness in rat airway smooth muscle cells (Tao et 
al., 2000). Although we do not know the exact mechanism of action for triclosan, it is 
hypothesized that augmentations in intracellular signaling events resulting in alternations in 
cytokine expression may be responsible for enhanced Th2 polarization.
In summary, triclosan was identified as a nonsensitizing chemical capable of augmenting the 
allergic response to a known allergen. Given the widespread use of this chemical, there is 
concern for its possible contribution to the rising incidence of allergic disease. Consistent 
with epidemiologic studies associating urinary triclosan levels and allergy, repeated dermal 
exposure to triclosan enhanced AHR, IgE, lung eosinophilic infiltration, and enhanced IL-13 
cytokine production in a mouse model of asthma. This is the first animal study to associate 
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triclosan with allergic disease. These results in addition to its high production volume, 
widespread applications, and endocrine-disrupting effects encourage additional 
investigations and increased awareness about triclosan exposure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of coexposure to triclosan and OVA on airway hyperreactivity. Nonspecific (A) and 
specific (B) airway hyperreactivity were evaluated in mice (eight per group) that were 
dermally exposed to triclosan for 28 days and sensitized with OVA on days 1 and 7 of the 
experiment and then challenged with OVA via pharyngeal aspiration on days 19 and 27. 
Nonspecific AHR was evaluated on day 21, and specific AHR was evaluated on day 27 
immediately following pulmonary challenge. Each point/line represents mean values 
(baseline subtracted) ± SE of eight mice per group. Levels of statistical significance are 
designated as * (p < 0.05) for all coexposure groups compared with the OVA control. The 
data graphed are the average Penh value plotted over the 6-h collection period for the OVA-
specific airway response.
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OVA-specific antibody production following coexposure to triclosan and OVA. Analysis of 
OVA-specific (A) IgE and (B) IgG1, following exposure to triclosan and OVA, was 
measured using an ELISA. Bars represent mean ± SE for each group of eight mice. 
Statistical significance (p ≤ 0.05) is designated as * compared with the OVA control or # 
compared with the VC.
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Effect of coexposure to triclosan and OVA on BAL infiltrates. Absolute numbers of (A) 
total BAL cells, (B) eosinophils, (C) neutrophils, and (D) macrophages evaluated in mice 
following exposure to triclosan + OVA. Error bars represent mean ± SE of seven mice per 
group. Statistical significance (p ≤ 0.05) is designated as * compared with the OVA control 
or # compared with the VC.
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Lung histopathology following coexposure to triclosan and OVA. Photomicrographs 
represent (A) lung of a VC mouse (bar = 50 μm); (B) lung of a mouse exposed to OVA and 
3% triclosan demonstrating peribronchiolar, vascular, and perivascular infiltrates with 
extension into alveolar spaces (bar = 50 μm); (C) higher magnifications of the lung from the 
mouse in B showing mucous metaplasia and peribronchiolar plasma cells and eosinophils 
(bar = 20 μm); (D) lung of a mouse exposed to OVA alone showing perivascular and 
peribronchiolar inflitrates with extension into alveolar spaces (bar = 50 μm).
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Effect of coexposure to triclosan and OVA on IL-13 mRNA cytokine production by the 
Lung. IL-13 mRNA expression was evaluated in mice following coexposure to triclosan + 
OVA. Error bars represent mean ± SE of four mice per group. Statistical significance (p ≤ 
0.05) is designated as * compared with the OVA control or # compared with the VC.
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Effect of coexposure to triclosan and OVA on cytokine production by the tracheobronchial 
lymph node. (A) IL-4, (B) IL-5, (C) IL-13, and (D) IFN-γ protein expression were evaluated 
by ELISA in ex vivo stimulated lymph node cells following coexposure to triclosan + OVA. 
Error bars represent mean ± SE of eight mice per group. Statistical significance (p ≤ 0.05) is 
designated as # compared with the VC.
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